Literature DB >> 20921899

Extreme genetic divergence is required for coreceptor switching in HIV-1 subtype C.

Mia Coetzer1, Rebecca Nedellec, Tonie Cilliers, Tammy Meyers, Lynn Morris, Donald E Mosier.   

Abstract

BACKGROUND: Coreceptor switching from CCR5 to CXCR4 is less common in subtype C HIV-1 infection than in subtype B for reasons that are unclear. We have examined sequential virus samples from a subtype C-infected child who had evidence of coreceptor switching.
METHODS: To examine HIV-1 envelope evolution towards CXCR4 usage, env sequences were correlated with phenotypic characteristics determined by entry assays, as well as the ability to use alternative coreceptors such as FPRL1, CCR3, CCR8 and others. The value of a phenotype predictor based on V3 sequences was also assessed.
RESULTS: Ninety-three sequences revealed 3 distinct coexistent virus lineages and only some members of one lineage evolved to use CXCR4. These lineages also had diverse alternative coreceptor patterns including the ability to use FPRL1, CCR3, CCR8, APJ, CMKLR1, RDC-1, CXCR6, CCR1, GPCR1, GPR15 and CCR6. Coreceptor switching was associated with extensive and rapid sequence divergence in the V1/V2 region in addition to V3 changes. Furthermore, interlineage recombination within the C2 region resulted in low predictability of a V3 sequence-based phenotype algorithm, and highlighted the importance of V1/V2 and V3 sequences in coreceptor usage.
CONCLUSION: These results suggest that the evolution to coreceptor switching in subtype C infection requires more mutations than other subtypes, and this contributes to the reduced incidence of R5X4 viruses.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 20921899      PMCID: PMC3006070          DOI: 10.1097/QAI.0b013e3181f63906

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  51 in total

1.  Genetic characteristics of the V3 region associated with CXCR4 usage in HIV-1 subtype C isolates.

Authors:  Mia Coetzer; Tonie Cilliers; Li-Hua Ping; Ronald Swanstrom; Lynn Morris
Journal:  Virology       Date:  2006-08-30       Impact factor: 3.616

2.  A reliable phenotype predictor for human immunodeficiency virus type 1 subtype C based on envelope V3 sequences.

Authors:  Mark A Jensen; Mia Coetzer; Angélique B van 't Wout; Lynn Morris; James I Mullins
Journal:  J Virol       Date:  2006-05       Impact factor: 5.103

3.  Changes in the V3 region of gp120 contribute to unusually broad coreceptor usage of an HIV-1 isolate from a CCR5 Delta32 heterozygote.

Authors:  Paul R Gorry; Rebecca L Dunfee; Megan E Mefford; Kevin Kunstman; Tom Morgan; John P Moore; John R Mascola; Kristin Agopian; Geoffrey H Holm; Andrew Mehle; Joann Taylor; Michael Farzan; Hui Wang; Philip Ellery; Samantha J Willey; Paul R Clapham; Steven M Wolinsky; Suzanne M Crowe; Dana Gabuzda
Journal:  Virology       Date:  2007-01-18       Impact factor: 3.616

4.  Longitudinal analysis of HIV type 1 subtype C envelope sequences from South Africa.

Authors:  Mia Coetzer; Tonie Cilliers; Maria Papathanasopoulos; Gita Ramjee; Salim Abdool Karim; Carolyn Williamson; Lynn Morris
Journal:  AIDS Res Hum Retroviruses       Date:  2007-02       Impact factor: 2.205

5.  Human immunodeficiency virus type 1 coreceptor switching: V1/V2 gain-of-fitness mutations compensate for V3 loss-of-fitness mutations.

Authors:  C Pastore; R Nedellec; A Ramos; S Pontow; L Ratner; D E Mosier
Journal:  J Virol       Date:  2006-01       Impact factor: 5.103

6.  Frequent intrapatient recombination between human immunodeficiency virus type 1 R5 and X4 envelopes: implications for coreceptor switch.

Authors:  Mattias Mild; Joakim Esbjörnsson; Eva Maria Fenyö; Patrik Medstrand
Journal:  J Virol       Date:  2007-01-24       Impact factor: 5.103

7.  Correlation between a phenotypic assay and three bioinformatic tools for determining HIV co-receptor use.

Authors:  Eva Poveda; Verónica Briz; Vanessa Roulet; María Del Mar González; Jean-Louis Faudon; Katharina Skrabal; Vincent Soriano
Journal:  AIDS       Date:  2007-07-11       Impact factor: 4.177

8.  Genotypic and phenotypic characterization of viral isolates from HIV-1 subtype C-infected children with slow and rapid disease progression.

Authors:  Isaac Choge; Tonie Cilliers; Polly Walker; Natasha Taylor; Mary Phoswa; Tammy Meyers; Johannes Viljoen; Avy Violari; Glenda Gray; Penny L Moore; Maria Papathanosopoulos; Lynn Morris
Journal:  AIDS Res Hum Retroviruses       Date:  2006-05       Impact factor: 2.205

9.  Current V3 genotyping algorithms are inadequate for predicting X4 co-receptor usage in clinical isolates.

Authors:  Andrew J Low; Winnie Dong; Dennison Chan; Tobias Sing; Ronald Swanstrom; Mark Jensen; Satish Pillai; Benjamin Good; P Richard Harrigan
Journal:  AIDS       Date:  2007-09-12       Impact factor: 4.177

10.  Virus entry via the alternative coreceptors CCR3 and FPRL1 differs by human immunodeficiency virus type 1 subtype.

Authors:  R Nedellec; M Coetzer; N Shimizu; H Hoshino; V R Polonis; L Morris; U E A Mårtensson; J Binley; J Overbaugh; D E Mosier
Journal:  J Virol       Date:  2009-06-24       Impact factor: 5.103

View more
  17 in total

Review 1.  Coreceptors and HIV-1 pathogenesis.

Authors:  Paul R Gorry; Petronela Ancuta
Journal:  Curr HIV/AIDS Rep       Date:  2011-03       Impact factor: 5.071

2.  Effect of Amino Acid Substitutions Within the V3 Region of HIV-1 CRF01_AE on Interaction with CCR5-Coreceptor.

Authors:  Sayamon Hongjaisee; Martine Braibant; Francis Barin; Nicole Ngo-Giang-Huong; Wasna Sirirungsi; Tanawan Samleerat
Journal:  AIDS Res Hum Retroviruses       Date:  2017-06-12       Impact factor: 2.205

3.  HIV-1 pathogenesis: the virus.

Authors:  Ronald Swanstrom; John Coffin
Journal:  Cold Spring Harb Perspect Med       Date:  2012-12-01       Impact factor: 6.915

4.  High-Sequence Diversity and Rapid Virus Turnover Contribute to Higher Rates of Coreceptor Switching in Treatment-Experienced Subjects with HIV-1 Viremia.

Authors:  Rebecca Nedellec; Joshua T Herbeck; Peter W Hunt; Steven G Deeks; James I Mullins; Elizabeth D Anton; Jacqueline D Reeves; Donald E Mosier
Journal:  AIDS Res Hum Retroviruses       Date:  2016-10-12       Impact factor: 2.205

5.  Mechanisms of HIV-1 subtype C resistance to GRFT, CV-N and SVN.

Authors:  Kabamba B Alexandre; Penny L Moore; Molati Nonyane; Elin S Gray; Nthabeleng Ranchobe; Ereck Chakauya; James B McMahon; Barry R O'Keefe; Rachel Chikwamba; Lynn Morris
Journal:  Virology       Date:  2013-08-15       Impact factor: 3.616

6.  Evolution of HIV-1 coreceptor usage and coreceptor switching during pregnancy.

Authors:  Doris G Ransy; Alena Motorina; Natacha Merindol; Bertine S Akouamba; Johanne Samson; Yolanda Lie; Laura A Napolitano; Normand Lapointe; Marc Boucher; Hugo Soudeyns
Journal:  AIDS Res Hum Retroviruses       Date:  2013-10-25       Impact factor: 2.205

7.  Longitudinal Analysis of CCR5 and CXCR4 Usage in a Cohort of Antiretroviral Therapy-Naïve Subjects with Progressive HIV-1 Subtype C Infection.

Authors:  Martin R Jakobsen; Kieran Cashin; Michael Roche; Jasminka Sterjovski; Anne Ellett; Katharina Borm; Jacqueline Flynn; Christian Erikstrup; Maelenn Gouillou; Lachlan R Gray; Nitin K Saksena; Bin Wang; Damian F J Purcell; Per Kallestrup; Rutendo Zinyama-Gutsire; Exnevia Gomo; Henrik Ullum; Lars Ostergaard; Benhur Lee; Paul A Ramsland; Melissa J Churchill; Paul R Gorry
Journal:  PLoS One       Date:  2013-06-18       Impact factor: 3.240

Review 8.  Escape from human immunodeficiency virus type 1 (HIV-1) entry inhibitors.

Authors:  Christopher J De Feo; Carol D Weiss
Journal:  Viruses       Date:  2012-12       Impact factor: 5.048

Review 9.  HIV-1 induced bystander apoptosis.

Authors:  Himanshu Garg; Jonathon Mohl; Anjali Joshi
Journal:  Viruses       Date:  2012-11-09       Impact factor: 5.048

10.  CoRSeqV3-C: a novel HIV-1 subtype C specific V3 sequence based coreceptor usage prediction algorithm.

Authors:  Kieran Cashin; Lachlan R Gray; Martin R Jakobsen; Jasminka Sterjovski; Melissa J Churchill; Paul R Gorry
Journal:  Retrovirology       Date:  2013-02-27       Impact factor: 4.602

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.